Author: Marilyn

Omicron 4.3 Trial Shows Strong Protection against COVID-19

Omicron 4.3 Trial Shows Strong Protection against COVID-19

Toronto to ramp up COVID-19 vaccine clinic operations in response to Omicron 4.3 trial results. Global Vaccine Access (GVA) announced it is starting to implement Omicron 4.3 into its clinics.

“This announcement is incredibly hopeful and exciting news,” GVA CEO Dr. James Peacock said. “We are thrilled that Omicron has confirmed strong protection against COVID-19 in the Omicron 4.3 trial,” said Dr. James Peacock, GVA Chief Executive Officer. “The results will have a significant impact on the vaccine clinic network and we have to work hard to prepare in anticipation.”

“We are thrilled our Omicron trial shows robust and potent protection against COVID-19. The strong findings will have a significant impact on the vaccine clinic network and we have to work hard to prepare in anticipation.”

GVA is a vaccine clinic network. Since 2006, GVA clinics have delivered safe and effective vaccines to over 100 million people. GVA clinics use the most proven immunizations and have been delivering vaccines to patients for more than 20 years. GVA is an innovative Canadian vaccine delivery network that was launched in 2012 and has successfully been delivering vaccines to over 100 million patients since then.

In the Omicron 4.3 trial, the vaccine was administered to over 50,000 people, with more than 20,000 immune responders enrolled from more than 600 clinics in North America, Australia, and New Zealand.

In the trial, nearly half the vaccinated participants developed COVID-19 antibodies, which means their immune system had recognized COVID-19 (nearly 80% across all age groups).

GVA also says researchers are “hopeful” the trial also identified potential cross-reactive antibodies among the groups in the trial (i.e., people who have been infected with multiple viruses that produce coronaviruses) that could provide further protection.

“We are extremely excited about this result as it marks a significant milestone both in our research and in the vaccine clinic network,” GVA’s Peacock said. “The results of the Omicron 4.3 study will have a significant impact on the vaccine clinic network and are truly a big step forward in our mission of improving health and well-being

Leave a Comment